Evening lecture by Dr. Peter van Wezenbeek organized by the Rotterdamsche Chemische Kring.

Epigenetics

Summary
Epigenetics is a word derived from the Greek ‘epi’ and ‘genetics’. It indicates that there is something more to genetics than we already know. From molecular biology, we know the basis of genetics: DNA, a polymer made up of four elements. The sequence of these, also known as the genome, determines the sequence of the amino acids in our proteins. However, this sequence also determines the binding of certain proteins to the DNA, thereby regulating gene expression. This entire process is passed on to the daughter cell and even forms the basis of our evolution. Consequently, changes in this system do not occur very quickly. Epigenetics is an additional and faster molecular biological gene regulation system, a system that therefore works in conjunction with the previously known system.

The epigenome can be seen as the language through which the genome communicates with its environment. Modifications are then made, allowing genes to be regulated differently. They do not alter the sequence of the DNA building blocks, but they do influence the level of gene expression. This can result in adaptation, but if things go wrong, it can also lead to maladaptation. The majority of these changes are therefore reversible. Epigenetic mechanisms are widespread across many life forms and result in phenotypic plasticity. We can now attribute an epigenetic explanation to many well-known phenomena in nature (including human diseases).

In this general molecular biology presentation on epigenetics, an insight will be provided into the molecular modifications of the genome and their consequences, as observed in various life forms. It is a particularly fascinating field concerning the regulation of life processes, though one which, unfortunately, is also subject to many misconceptions.

CV
Peter van Wezenbeek is a (retired) molecular biologist. He obtained his PhD for his work on the DNA sequence of one of the first fully sequenced genomes (bacteriophage M13). During various post-doctoral periods, he worked on plant viruses and viroids, transcription regulation and oncogenes. He then joined Organon, where he was responsible for the design and synthesis of a DNA molecule capable of expressing human follicle-stimulating hormone in a host cell, resulting in the synthesis of a recombinant DNA product for in vitro fertilisation (Puregon). In addition, his work also encompassed numerous other biotechnology projects, including the production of recombinant antibodies. In the second half of his career, he also qualified as a European patent attorney and, in that capacity at Organon, was responsible for various biotechnology and chemical projects.

Invitees are very welcome.

Please send an email to chemischekringrotterdam@gmail.com.